NTLA — INTELLIA THERAPEUTICS Share News
0.000.00%
Last trade - 00:00- $1.56bn
- $1.13bn
- $67.67m
Brief: Intellia Therapeutics Says One Dose Of NEX-Z Shows Durable TTR Reductions Of At Least 90% Through Three Years
U.S. STOCKS ON THE MOVE- Jefferies Financial, Amer Sports
U.S. STOCKS ON THE MOVE-GE Healthcare ,Intellia, Bullish
Intellia rises after enrolling patients in late-stage trial of genetic disorder drug
Brief: Intellia Completes Global Phase 3 HAELO Study Enrollment for Lonvo-Z in Hereditary Angioedema
Intellia Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Intellia Therapeutics Q2 Net Income USD -101.255 Million
Brief: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Gene-editing firms rise after Lilly strikes deal to acquire Verve Therapeutics
U.S. STOCKS ON THE MOVE-MercadoLibre, Crocs, Paycom Software
U.S. STOCKS ON THE MOVE-Tapestry, Carvana, PPG Industries
Intellia Therapeutics rises on narrower Q1 loss
Intellia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy
Brief: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)
H.C. Wainwright starts coverage on Intellia with 'buy' rating on optimism for heart disease therapies
U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp
U.S. STOCKS ON THE MOVE-Apple, Zevra Therapeutics, Agilent Technologies
Intellia Therapeutics jumps on better-than-expected Q4 collaboration revenue